ViGeneron GmbH

Nature Communications publication reveals highly efficient AAV delivery of large genes using ViGeneron´s REVeRT technology

ViGeneron announces EMA Approval of Clinical Trial Application for VG901, a gene therapy to treat Retinitis Pigmentosa

ViGeneron presents preclinical data on intravitreal gene therapy of Stargardt disease at ESGCT

ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases

ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target

ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

ViGeneron and WuXi Advanced Therapies enter Strategic Manufacturing Partnership for Next-Generation Ophthalmic Gene Therapy

ViGeneron announces closing of series A financing to drive development of next generation gene therapy pipeline